Database : MEDLINE
Search on : Venous and Thromboembolism [Words]
References found : 27048 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 2705 go to page                         

  1 / 27048 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524865
[Au] Autor:Zaccardi F; Kunutsor SK; Seidu S; Davies MJ; Khunti K
[Ad] Address:Diabetes Research Centre, University of Leicester, Leicester, UK. Electronic address: frazac@fastwebnet.it.
[Ti] Title:Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials.
[So] Source:Atherosclerosis;271:223-231, 2018 Mar 02.
[Is] ISSN:1879-1484
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:BACKGROUND AND AIMS: Meta-analyses of randomised controlled trials (RCTs) have suggested a possible benefit of statin treatment on the risk of venous thromboembolism (VTE), with potential differences by type and dose of statins. We aimed to assess differences among statins and to investigate the relationship between risk of VTE and reduction of LDL-cholesterol (LDL-c) levels. METHODS: We electronically searched, through November 29, 2017, RCTs comparing a statin with either placebo or another statin treatment, including 100 or more adult participants, and lasting at least 24 weeks. Data on first VTE events and LDL-c was analysed with a network meta-analysis and a meta-regression. RESULTS: Thirty RCTs (159,058 participants; 1431 events) were included, with 28 reporting LDL-c data. Network meta-analysis indicated a larger benefit for rosuvastatin compared to placebo and other statins; 50% of the effect of statins on VTE risk reduction, however, was explained by their different potencies in lowering LDL-c. The risk reduction in VTE was proportional to LDL-c decrease (37% relative lower risk per each 1 mmol/L reduction in LDL-c), without an apparent threshold. A reduction of 1 mmol/L in LDL-c would translate in 37 less VTE events per year in 100,000 people in UK, corresponding to 3162 prevented episodes per year in people between 50 and 59 years. CONCLUSIONS: In RCTs with statin treatment, the reduction of VTE risk was only partially related to LDL-c reduction and the benefit was larger than that observed for atherothrombotic risk. Further RCTs are warranted to clarify the relationship between statin, lipid modifications, and VTE risk.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 27048 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524713
[Au] Autor:Aoun SG; Bedros N; El Ahmadieh TY; Kreck J; Mehta N; Al Tamimi M
[Ti] Title:Osteodiscitis of the Lumbar Spine Due To a Migrated Fractured Inferior Vena Cava Filter: Case Report.
[So] Source:World Neurosurg;, 2018 Mar 07.
[Is] ISSN:1878-8769
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Venous thromboembolism can be a significant cause of morbidity in the trauma population. Medical and surgical specialties have been pushing the indication for prophylactic filter placement. CASE DESCRIPTION: A 36-year-old man presented with axial lower back pain with a radicular right L2 component after lifting a heavy object. He had a history of penetrating brain trauma 3 years prior, with placement of a prophylactic inferior vena cava filter. His x-ray, computed tomography, and magnetic resonance imaging of the lumbar spine showed fracture of his filter, with migration of the fractured fragment through the inferior vena cava and into the L2-L3 disc space, and surrounding bony lysis and severe osteodiscitis. He was treated medically with intravenous and then oral antibiotics and improved clinically and radiographically. CONCLUSIONS: Conservative use of filter devices and early retrieval once their indication expires is paramount to avoid unnecessary complications.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  3 / 27048 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523536
[Au] Autor:Popoola VO; Lau BD; Tan E; Shaffer DL; Kraus PS; Farrow NE; Hobson DB; Aboagye JK; Streiff MB; Haut ER
[Ad] Address:Division of Acute Care Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD.
[Ti] Title:Nonadministration of medication doses for venous thromboembolism prophylaxis in a cohort of hospitalized patients.
[So] Source:Am J Health Syst Pharm;75(6):392-397, 2018 Mar 15.
[Is] ISSN:1535-2900
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: Results of a study to characterize patterns of nonadministration of medication doses for venous thromboembolism (VTE) prevention among hospitalized patients are presented. METHODS: The electronic records of all patients admitted to 4 floors of a medical center during a 1-month period were examined to identify patients whose records indicated at least 1 nonadministered dose of medication for VTE prophylaxis. Proportions of nonadministered doses by medication type, intended route of administration, and VTE risk categorization were compared; reasons for nonadministration were evaluated. RESULTS: Overall, 12.7% of all medication doses prescribed to patients in the study cohort ( = 75) during the study period (857 of 6,758 doses in total) were not administered. Nonadministration of 1 or more doses of VTE prophylaxis medication was nearly twice as likely for subcutaneous anticoagulants than for all other medication types (231 of 1,112 doses [20.8%] versus 626 of 5,646 doses [11.2%], < 0.001). For all medications prescribed, the most common reason for nonadministration was patient refusal (559 of 857 doses [65.2%]); the refusal rate was higher for subcutaneous anticoagulants than for all other medication categories (82.7% versus 58.8%, < 0.001). Doses of antiretrovirals, immunosuppressives, antihypertensives, psychiatric medications, analgesics, and antiepileptics were less commonly missed than doses of electrolytes, vitamins, and gastrointestinal medications. CONCLUSION: Scheduled doses of subcutaneous anticoagulants for hospitalized patients were more likely to be missed than doses of all other medication types.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Data-Review
[do] DOI:10.2146/ajhp161057

  4 / 27048 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29522911
[Au] Autor:Lee YH; Cha SI; Shin KM; Lim JK; Yoo SS; Lee SY; Lee J; Kim CH; Park JY; Lee WK
[Ad] Address:Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
[Ti] Title:Clinical relevance of syncope in patients with pulmonary embolism.
[So] Source:Thromb Res;164:85-89, 2018 Mar 02.
[Is] ISSN:1879-2472
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Syncope is an unusual clinical manifestation of pulmonary embolism (PE), and the clinical significance of syncope in PE patients remains controversial. We investigated the incidence of syncope, examined the clinical factors associated with syncope, and assessed the association between syncope and the short-term outcomes of PE. METHODS: We retrospectively classified patients presenting with PE into 2 groups: patients with syncope and those without syncope. We compared the clinical and computed tomography parameters between the groups. RESULTS: Among 1084 patients diagnosed with PE, 45 (4.2%) presented with syncope. Four patients which presented with cardiac arrest were excluded from the study. The syncope group showed significantly higher blood biomarker levels and higher rates of central PE and right ventricular dilation than the control group. Unprovoked PE (odds ratio [OR] 8.046, 95% confidence interval [CI] 3.073-21.069, p < 0.001), female sex (OR 3.419, 95% CI 1.348-8.675, p = 0.010), central PE (OR 2.854, 95% CI 1.298-6.278, p = 0.009), and troponin I level (OR 2.812, 95% CI 1.765-4.480, p < 0.001) were observed to be independent factors associated with syncope in PE patients. However, multivariate analysis showed that the presence of syncope was not a significant predictor of adverse outcomes and recurrent venous thromboembolism in PE patients. CONCLUSIONS: Although syncope is associated with a more severe form of PE, it does not influence the short-term prognosis of PE. Central PE, blood troponin I level, unprovoked PE, and female sex were observed to be clinical factors related with syncope in patients with PE.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  5 / 27048 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29522910
[Au] Autor:Delluc A; Ianotto JC; Tromeur C; De Moreuil C; Couturaud F; Lacut K; Le Moigne E; Louis P; Thereaux J; Metges JP; Mottier D
[Ad] Address:EA 3878 (GETBO), Brest University, 29200 Brest, France; Department of Chest Diseases and Internal Medicine, Hpital de la Cavale Blanche, 29609 Brest Cedex, France. Electronic address: aurelien.delluc@chu-brest.fr.
[Ti] Title:Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study.
[So] Source:Thromb Res;164:79-84, 2018 Mar 02.
[Is] ISSN:1879-2472
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Venous thromboembolism (VTE) can be the first manifestation of cancer; however, the current incidence of malignancy in unselected patients with first unprovoked VTE needs to be confirmed. MATERIAL AND METHODS: Between March 1st, 2013 and February 28th, 2015 we included and followed-up all patients living in the Brest district, France, who were seen in hospitals or the community for a first symptomatic unprovoked VTE event. The primary study outcome was the one-year incidence of cancer. RESULTS: 526 patients, mean age 66.6  18.1 years, 246 (46.8%) men, were included in the study. In the year following VTE, 26 patients were diagnosed with cancer, corresponding to a one-year cumulative incidence of cancer of 5.06% (95% CI 3.47-7.35). Age ≥60, smoking and pulmonary embolism were significantly associated with cancer diagnosis in multivariate analysis. Fifty percent of cancers were patent at the time of VTE diagnosis, mostly detected on CTPA (Computed Tomographic Pulmonary Angiography) performed for pulmonary embolism assessment. After excluding patients with patent cancer at VTE diagnosis, the one-year incidence of cancer was 2.65% (95% CI: 1.55-4.52); in multivariate analysis, only current smoking was independently associated with a significant 5.4-fold increased risk for cancer diagnosis (HR 5.40; 95% CI 1.31-22.27). No cancer was diagnosed in patients aged 50 years or younger. CONCLUSION: The one-year incidence of cancer after a first unprovoked VTE was 5.06%. Half of the cancers were diagnosed during the diagnosis procedure for pulmonary embolism using CTPA.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  6 / 27048 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29522396
[Au] Autor:Bartholomew JR
[Ad] Address:Section Head, Department of Vascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. barthoj@ccf.org.
[Ti] Title:Correction: Update on VTE.
[So] Source:Cleve Clin J Med;85(3):189, 2018 Mar.
[Is] ISSN:1939-2869
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:In the article, "Update on the management of venous thromboembolism" (Bartholomew JR, Cleve Clin J Med 2017; 84[suppl 3]:39-46), 2 sentences in the text regarding dose reduction for body weight have errors. The corrected sentences follow: On page 42, left column, the last 5 lines should read: "The recommended dose should be reduced to 2.5 mg twice daily in patients that meet 2 of the following criteria: age 80 or older; body weight of 60 kg or less; or with a serum creatinine 1.5 mg/dL or greater." And on page 42, right column, the sentence 10 lines from the top should read: "Edoxaban is given orally at 60 mg once daily but reduced to 30 mg once daily if the CrCL is 30 mL/min to 50 mL/min, if body weight is 60 kg or less, or with use of certain P-glycoprotein inhibitors."
[Pt] Publication type:PUBLISHED ERRATUM
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review

  7 / 27048 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29505518
[Au] Autor:Zhang S; Huang Q; Xu B; Ma J; Cao G; Pei F
[Ad] Address:Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
[Ti] Title:Effectiveness and safety of an optimized blood management program in total hip and knee arthroplasty: A large, single-center, retrospective study.
[So] Source:Medicine (Baltimore);97(1):e9429, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Little has been published on blood management in total hip and knee arthroplasty (THA and TKA, respectively) patients focusing on both hematopoiesis and hemostasis. Our aim was to explore the effectiveness and safety of an optimized blood management program in THA and TKA patients in a large, single-center, retrospective study.We retrospectively reviewed consecutive primary unilateral THA and TKA patients' data at our institution through the National Health Database. They were divided into 3 groups according to an optimized blood management program: group A-combined use of intravenous and topical tranexamic acid (TXA); group B-use of recombinant human erythropoietin (rHuEPO) and iron supplements in addition to treatments in group A; group C-use of additional multiple boluses of TXA in addition to treatments in group B. The primary outcomes were hemoglobin (Hb) drop and calculated total blood loss (TBL). Other outcome measurements such as transfusion rate, postoperative length of stay (PLOS), venous thromboembolism (VTE), and mortality were also compared.From 2014 to 2016, a total of 1907 unilateral THA (986 in group A, 745 in group B, and 176 in group C) and 1505 unilateral TKA (795 in group A, 556 in group B, and 154 in group C) procedures were conducted at our institution. The Hb drop, calculated TBL, and PLOS in group C were significantly lower than those in groups A and B for THA and TKA patients. The transfusion rate in group C was also significantly less than in groups A and B for THA patients, while it was similar in groups A and B for TKA patients. No patients in group C received a transfusion. A significant difference was not detected in the incidence of deep vein thrombosis. No episode of symptomatic pulmonary embolism or all-cause mortality occurred within 30 days postoperatively.The current retrospective study suggests that for patients receiving primary unilateral THA or TKA, multiple boluses of intravenous TXA combined with topical TXA, rHuEPO, and iron supplements can reduce the calculated TBL, Hb drop, transfusion rate, and PLOS without increasing the incidence of VTE or mortality.
[Mh] MeSH terms primary: Anemia/drug therapy
Antifibrinolytic Agents/administration & dosage
Blood Loss, Surgical/prevention & control
Erythropoietin/therapeutic use
Iron/therapeutic use
Trace Elements/therapeutic use
Tranexamic Acid/administration & dosage
[Mh] MeSH terms secundary: Administration, Intravenous
Administration, Topical
Adult
Aged
Anemia/etiology
Arthroplasty, Replacement, Hip/adverse effects
Arthroplasty, Replacement, Knee/adverse effects
Female
Humans
Male
Middle Aged
Recombinant Proteins/therapeutic use
Retrospective Studies
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antifibrinolytic Agents); 0 (Recombinant Proteins); 0 (Trace Elements); 11096-26-7 (Erythropoietin); 6T84R30KC1 (Tranexamic Acid); E1UOL152H7 (Iron)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009429

  8 / 27048 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29428851
[Au] Autor:Shim JY; Patel A
[Ad] Address:Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Division of Family Planning, Obstetrics and Gynecology, The John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA. Electronic address: jessica-shim@northwestern.edu.
[Ti] Title:Therapeutic anticoagulation for pulmonary embolism during first-trimester surgical abortion: two case reports.
[So] Source:Contraception;, 2018 Feb 08.
[Is] ISSN:1879-0518
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:We report two patients with bilateral pulmonary embolism who presented to our county hospital reproductive health services clinic. Both patients underwent an uncomplicated first-trimester aspiration abortion while on therapeutic unfractionated heparin therapy. Anticoagulation therapy may be modified to safely perform first-trimester surgical termination without significant blood loss.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  9 / 27048 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29257737
[Au] Autor:Bartholomew JR
[Ad] Address:Section Head, Department of Vascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. barthoj@ccf.org.
[Ti] Title:Update on the management of venous thromboembolism.
[So] Source:Cleve Clin J Med;84(12 Suppl 3):39-46, 2017 Dec.
[Is] ISSN:1939-2869
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is a common cardiovascular disease associated with significant morbidity ranging from painful leg swelling, chest pain, shortness of breath, and even death. Long-term complications include recurrent VTE, postpulmonary embolism syndrome, chronic thromboembolic pulmonary hypertension, and postthrombotic syndrome (PTS). Management of VTE requires immediate anticoagulation therapy based on a risk assessment for bleeding. Direct oral anticoagulants (DOACs) have become an important option for patients as reflected in the most recent American College of Chest Physician treatment guidelines.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1712
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.3949/ccjm.84.s3.04

  10 / 27048 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29521284
[Au] Autor:Li ZJ; Zhao MW; Zeng L
[Ad] Address:Department of Orthopaedics, Peking University Third Hospital, Beijing 100191, China.
[Ti] Title:Additional Dose of Intravenous Tranexamic Acid after Primary Total Knee Arthroplasty Further Reduces Hidden Blood Loss.
[So] Source:Chin Med J (Engl);131(6):638-642, 2018 Mar 20.
[Is] ISSN:0366-6999
[Cp] Country of publication:China
[La] Language:eng
[Ab] Abstract:Background: Total knee arthroplasty (TKA) is the most frequently performed procedure in treating advanced knee osteoarthritis. Excessive perioperative blood loss can sometimes lead to postoperative anemia. Tranexamic acid (TXA) is a potent fibrinolysis inhibitor which has been extensively used at the surgical incision and closure to lower overall blood loss in adult reconstruction surgery. Our previous study suggested that about two-thirds of the total blood loss (TBL) came from hidden blood loss (HBL) on postoperative days 1 and 2. The role of reducing HBL with TXA administration in postoperative TKA patients is unknown. The current study was designed to evaluate the efficiency and safety of supplemental intravenous (IV) TXA in further reducing HBL after primary TKA. Methods: A prospective pilot study was conducted at a single institution on 43 consecutive patients who underwent unilateral TKA from September 2014 to February 2015. All patients were given 1 g of IV TXA 10-15 min before operation and another 1 g of IV TXA at the time of wound closure on the day of surgery. On postoperative days 1 and 2, the supplemental group (n = 21) was given additional 1 g of TXA intravenously twice a day, whereas the control group (n = 22) received an equal volume of saline. Drain output, hemoglobin (Hb), and hematocrit (HCT) were recorded preoperatively and 5 consecutive days postoperatively in both groups. HBL was calculated with the Gross formula. Pre- and post-operative lower extremity Doppler venous ultrasound was performed in all patients to detect deep vein thrombosis (DVT). The indexes were compared using the Mann-Whitney test, whereas the results of Hb and HCT were analyzed by repeated-measures analysis of variance. The difference was considered statistically significant if P < 0.05. Results: The demographics and surgical characteristics of the two groups were comparable. Supplemental group had higher Hb level on postoperative days 1-5 compared to the control; however, the difference was not significant (F = 2.732, P = 0.106). The HCT of the supplemental group was significantly higher than that of the control group on postoperative day 5 (F = 5.254, P = 0.027). No significant difference was found in drainage volume and TBL, but the HBL was reduced in the supplemental group (supplemental 133.1 [71.8, 287.3] ml and control 296.0 [185.3, 421.4] ml, Z = 2.478, P = 0.013, median [interquartile range]). There was one DVT in the control group and none in the supplemental group. All patients were followed at 1 year after surgery, and no further complications were reported. Conclusion: Based on the current study, additional doses of IV TXA could potentially further reduce HBL after primary TKA without increasing the risk of venous thromboembolism.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.4103/0366-6999.226884


page 1 of 2705 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information